Navigation Links
Quanticel Pharmaceuticals Enters Into Strategic Cancer Drug Discovery Collaboration With Celgene Corporation
Date:11/4/2011

his scientific collaboration and this business model as an innovative approach with high potential to advance the delivery of impactful cancer drugs to patients in need."

The collaboration utilizes an innovative funding structure between Quanticel, Celgene and Versant Ventures.  Versant and Celgene have worked together to capitalize Quanticel at an early juncture, providing Versant with a strategic partner and potential acquirer, and Celgene with early and exclusive access to an R&D engine capable of fostering breakthrough therapies for patients at an accelerated pace.

"Aligning our financing strategy to create a start-up that supports the needs of a pre-eminent global biopharmaceutical company such as Celgene should build even greater value and liquidity than the traditional biotech venture approach," said Bradley Bolzon, Ph.D., Managing Director, Versant Ventures.

About Quanticel Pharmaceuticals

Quanticel Pharmaceuticals is a private, independent drug discovery company committed to creating breakthrough medicines for the treatment of cancer and other life-threatening diseases.  Quanticel's proprietary platform for the single-cell genomic analysis of human cancer is based on the work of company founders and Stanford professors Stephen Quake and Michael Clarke.  Quanticel brings together pioneering academic serial entrepreneurs, proven industry talent who have produced marketed drugs and high-value liquidity events, and top-tier Bay Area investor Versant Ventures.  The Company is headquartered in San Francisco, California.  For more information, please visit the Company's website at www.quanticel.com.

About Celgene

Celgene Corporation is an integrated global biopharmaceutical company engaged primarily in the discovery, development and commercialization of innovative therapies for the treatment of cancer and inflammatory diseases through gene
'/>"/>

SOURCE Quanticel Pharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... , Sept. 23, 2014 EnzymeBioSystems (OTCBB: ... along with the process of evaluating an enzyme ... in fighting tumors. In an effort to evaluate this ... with various contract research organizations to enlist their ... the use of an antitumor natural product called ...
(Date:9/23/2014)... Pa. , Sept. 23, 2014 The Pennsylvania ... drugs Sat., Sept. 27, as part of National Prescription ... no questions asked. Take-Back Day is a ... Enforcement Administration (DEA), aimed at encouraging the public to ... are prone to abuse and theft. From ...
(Date:9/23/2014)... , September 23, 2014 ... related disorders and increasing number of foreign and domestic ... probiotic in India   ... of the most high growth potential markets worldwide due ... consumers especially among the youth, changing food consumption patterns, ...
Breaking Medicine Technology:EnzymeBioSystems Announces Progress with an Enzyme Compound 2India Probiotic Market Pegged to Grow at Around 20% by 2019, Says TechSci Research 2India Probiotic Market Pegged to Grow at Around 20% by 2019, Says TechSci Research 3
... LAKE, N.J., Nov. 9 Par Pharmaceutical Companies, Inc. ... extended the expiration date and increased the purchase price ... in which Par is offering to purchase, for cash, ... approximately 82.7%, of its outstanding 2.875% Senior Subordinated Convertible ...
... , NEW YORK, Nov. 9 MISSION Skincare®, the ... soccer professional Mia Hamm, and other world class athletes, ... beauty aisle of more than 5,000 CVS/pharmacy locations across ... face, body and sun care products, MISSION and CVS/pharmacy ...
Cached Medicine Technology:Par Pharmaceutical Announces Extension and Increase in Maximum Purchase Price for 'Modified Dutch Auction' Tender Offer to Purchase up to $65,000,000 Aggregate Principal Amount of its Currently Outstanding 2.875% Senior Subordinated Convertible Note 2Par Pharmaceutical Announces Extension and Increase in Maximum Purchase Price for 'Modified Dutch Auction' Tender Offer to Purchase up to $65,000,000 Aggregate Principal Amount of its Currently Outstanding 2.875% Senior Subordinated Convertible Note 3Glamour Magazine Woman of the Year and MISSION Skincare Co-Founder, Serena Williams, Teams Up with CVS/pharmacy to Launch National 'Active Lifestyle Skincare Destinations' 2Glamour Magazine Woman of the Year and MISSION Skincare Co-Founder, Serena Williams, Teams Up with CVS/pharmacy to Launch National 'Active Lifestyle Skincare Destinations' 3
(Date:9/23/2014)... A new analysis of published studies found that ... cancer versus benign disease in regions where infections ... of lung lesions suspicious for cancer could lead ... additional potential complications and mortality. , Histoplasmosis ... that are often concentrated in bird droppings and ...
(Date:9/23/2014)... California, Davis, and Academia Sinica, the preeminent academic ... entered into a collaborative agreement to develop a ... cutting-edge research with opportunities to translate innovative technologies ... The agreement was signed Sept.12 in Taipei by ... Davis and President Chi-Huey Wong of Academia Sinica. ...
(Date:9/23/2014)... From first-hand experience, Matthew O'Farrell knows ... how it can be treated. , A medically retired ... 2006. His platoon sustained multiple attacks resulting in five ... with combat-related PTSD and honorably discharged from the Army. ... had distanced myself from my friends and family,” recalled ...
(Date:9/23/2014)... As a consumer in today’s world, ... It’s difficult to trust testimonials that are supplied by ... manipulate their customers into saying anything. , Consumer advocacy ... to lack in depth coverage on a particular market ... to fix this issue and focus on exposing the ...
(Date:9/23/2014)... HealthDay Reporter TUESDAY, Sept. 23, 2014 (HealthDay ... breast milk is more likely than a blood transfusion to ... a new study finds. The researchers evaluated more than ... weighed 3.3 pounds or less and many who were born ... whether breast milk or transfusions carried the bigger risk. Infants ...
Breaking Medicine News(10 mins):Health News:Study questions accuracy of lung cancer screens in some geographic regions 2Health News:Academia Sinica, UC Davis sign agreement on exchanges and tech transfer 2Health News:Virtual Reality software to help treat PTSD 2Health News:Virtual Reality software to help treat PTSD 3Health News:Consumer Health Reports Debuts Revolutionary Review Website 2Health News:Breast Milk a Risk for Spreading Common Virus to Preemies, Study Finds 2Health News:Breast Milk a Risk for Spreading Common Virus to Preemies, Study Finds 3
... heart expert calls it ,second-line, medication , , FRIDAY, ... the highly promoted cholesterol-lowering drug Vytorin continued Friday ... the medication,s effectiveness, but only after final trial ... this month when preliminary results of the so-called ...
... WellPoint, Inc. (NYSE:,WLP) announced today that senior ... Conference on January 30, 2008. The presentation is,expected ... All interested parties are invited to listen ... http://www.wellpoint.com and selecting the "Investor,Info" link. Following ...
... Ronit Calderon-Margalit, MD, MPH, Marianna Mazar, MD and Zvi ... Jewish and Arab diabetes sufferers who were admitted to ... whether differences existed between the two groups and, if ... health insurance coverage. The researchers found significant differences. As ...
... Jan. 25 Pizza, nachos, dip and wings ... also have one thing in common:,they can all ... counter heartburn medicine based on dollar sales, is ... tasty heartburn-friendly,alternatives., , Listen to this report ...
... Belgium have significantly advanced the discovery of a pancreatic ... beta cells. If the finding made in mice holds ... obvious target for therapeutic regeneration of beta cells in ... of the research journal Cell, a publication of Cell ...
... The North Carolina,Association of Educators (NCAE) will launch a ... at increasing awareness about good eating,habits and physical fitness ... from NCAE," is slated to run in,newspapers across North ... NCAE logo -- star in an ad campaign to,encourage ...
Cached Medicine News:Health News:FDA Will Wait for Trial Results on Vytorin 2Health News:FDA Will Wait for Trial Results on Vytorin 3Health News:WellPoint Announces Appearance at Upcoming Conference 2Health News:Elusive pancreatic progenitor cells found in mice 2Health News:NCAE Encourages Minority Youth and Their Families to 'Go-for' Health and Fitness 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: